Strategies for inducing effective neutralizing antibody responses against HIV-1.

abstract：:Plasmid DNA is a promising vaccine modality that is regularly examined in prime-boost immunization regimens. Recent advances in skin immunity increased our understanding of the sophisticated cutaneous immune network, which revived scientific interest in delivering vaccines to the skin. Intradermal administration of pl...

journal_title：Expert review of vaccines

authors： Elnekave M,Furmanov K,Hovav AH

更新日期：2011-08-01 00:00:00

abstract：:Several studies have identified an association between Pandemrix(TM), an AS03 adjuvanted pandemic influenza A(H1N1) vaccine, and narcolepsy, a rare and under-diagnosed sleep disorder with a median onset-to-diagnosis interval of ten years. This paper reviews potential sources of bias in published studies and aims to pr...

journal_title：Expert review of vaccines

authors： Wijnans L,Dodd C,de Ridder M,Romio S,Weibel D,Overeem S,Lammers GJ,Bonhoeffer J,Black S,Sturkenboom M

更新日期：2016-05-01 00:00:00

abstract：:The USA is experiencing a pertussis resurgence that resulted in a 60-year high of 48,000 cases in 2012. Our ability to counteract this resurgence is hampered by the fact that pertussis pathogenesis and immunity to pertussis infection are not well studied. Studies in humans are difficult due to the low frequency of per...

journal_title：Expert review of vaccines

authors： Warfel JM,Merkel TJ

更新日期：2014-10-01 00:00:00

abstract：:This section deals with how new knowledge of the development of cellular immunity in the neonatal period informs vaccine development and reviews the immune responses of the most vulnerable group of newborns, those born prematurely, to vaccines. It describes how the development of future vaccine strategies relies on a ...

journal_title：Expert review of vaccines

authors： Prescott S

更新日期：2004-08-01 00:00:00

abstract：:Therapeutic prospects of particulates are increasingly recognized for vaccination purposes. Compared with biologic particulates, such as live or attenuated bacterial vectors and viral vectors, synthetic particulates may be expected to ease the hurdles of quality assurance and validation in vaccine development and prod...

journal_title：Expert review of vaccines

authors： Thiele L,Merkle HP,Walter E

更新日期：2002-08-01 00:00:00

abstract：:Vaccine distribution and delivery has become an issue of significant interest, given the threat of a pandemic influenza outbreak and the resulting need for coordinated efforts to distribute and deliver pandemic influenza vaccines into the hands of healthcare workers responsible for administering them. This review prov...

journal_title：Expert review of vaccines

authors： Jacobson SH,Sewell EC,Jokela JA

更新日期：2007-12-01 00:00:00

abstract：:The Leishmania donovani glycoprotein fraction, known as FML, successfully underwent preclinical and clinical (Phase I-III) vaccine trials against canine visceral leishmaniasis (92-95% of protection and 76-80% of vaccine efficacy) when formulated with a QS21 saponin-containing adjuvant. It became the licensed Leishmune...

journal_title：Expert review of vaccines

authors： Palatnik-de-Sousa CB,Barbosa Ade F,Oliveira SM,Nico D,Bernardo RR,Santos WR,Rodrigues MM,Soares I,Borja-Cabrera GP

更新日期：2008-08-01 00:00:00

abstract：:Several live-attenuated Shigella vaccines, with well-defined mutations in specific genes, have shown great promise in eliciting significant immune responses when given orally to volunteers. These responses have been measured by evaluating antibody-secreting cells, serum antibody levels and fecal immunoglobulin A to ba...

journal_title：Expert review of vaccines

authors： Venkatesan MM,Ranallo RT

更新日期：2006-10-01 00:00:00

abstract：:Efforts to develop a meningococcal vaccine that will include coverage against serogroup B disease have largely focused on outer membrane protein antigens. The protection offered by currently licensed outer membrane vesicle (OMV) vaccines is specific to epidemic strains as their immunodominant antigens are highly varia...

journal_title：Expert review of vaccines

authors： Sanders H,Feavers IM

更新日期：2011-03-01 00:00:00

abstract：:Several new lyssaviruses have emerged in the past decade and it is likely that more remain to be discovered. There are six recognized genotypes of lyssavirus other than the rabies virus (genotype 1). All but one of these has been associated with human cases, with the resulting disease clinically similar to rabies. Rab...

journal_title：Expert review of vaccines

authors： Nel LH

更新日期：2005-08-01 00:00:00

abstract：:The available vaccines against human papillomavirus have some limitations such as low coverage due to their high cost, reduced immune coverage and the lack of therapeutic effects. Recombinant vaccines produced in plants (genetically engineered using stable or transient expression systems) offer the possibility to obta...

journal_title：Expert review of vaccines

authors： Rosales-Mendoza S,Govea-Alonso DO

更新日期：2015-07-01 00:00:00

abstract：:Extensive efforts aimed at stimulating immune responses by modifying HIV antigens and using various delivery systems and adjuvants have so far failed to generate promising HIV vaccines, highlighting the urgent need to explore alternative immunization approaches. Antigen-presenting cells, such as dendritic cells, play ...

journal_title：Expert review of vaccines

authors： Song XT,Aldrich M,Chen SY

更新日期：2006-08-01 00:00:00

abstract：:EVALUATION OF: Donato CM, Ch’ng LS, Boniface KF et al. Identification of strains of RotaTeq rotavirus vaccine in infants with gastroenteritis following routine vaccination. J. Infect. Dis. 206(3), 377–383 (2012).Two live, attenuated rotavirus vaccines, RotaTeq(®) (Merck) and Rotarix(®) (GlaxoSmithKline), have been use...

journal_title：Expert review of vaccines

authors： Bowen MD,Payne DC

更新日期：2012-11-01 00:00:00

abstract：:Adjuvants are essential components of most clinically used vaccines. This is because the majority of nonliving vaccines are relatively poor inducers of adaptive immunity unless effective adjuvants are co-administered. Aluminum salts (alum) have been used as adjuvants with great success for almost a century and have be...

journal_title：Expert review of vaccines

authors： Schijns VE,Lavelle EC

更新日期：2011-04-01 00:00:00

abstract：:Recombinant, nonreplicating, human adenovirus serotype 5-vectored vaccine, known as MRKAd5, expressing three HIV-1 clade B-derived internal proteins when used in a homologous immunization regimen, did not decrease HIV-1 infection rate nor postinfection virus load in the first Phase IIb proof-of-concept trial. However,...

journal_title：Expert review of vaccines

authors： Hanke T

更新日期：2008-04-01 00:00:00

abstract：:Protection against acquisition of fully heterologous, neutralization-resistant SIV was achieved in rhesus monkeys with adenovirus/poxvirus vector-based vaccines. Protection against acquisition of infection required the inclusion of envelope antigens and correlated with the induction of binding antibodies against the E...

journal_title：Expert review of vaccines

authors： Esparza J

更新日期：2012-05-01 00:00:00

abstract：:Introduction: Influenza vaccination is regarded as the most effective way to prevent influenza infection. Due to the rapid genetic changes that influenza viruses undergo, seasonal influenza vaccines must be reformulated and re-administered annually necessitating the evaluation of influenza vaccine effectiveness (VE) e...

journal_title：Expert review of vaccines

authors： Ainslie KEC,Haber M,Orenstein WA

更新日期：2019-06-01 00:00:00

abstract：:Immunocompromised hosts are growing in number and include transplant recipients of solid organs or hematopoietic stem cells, people who have HIV, cancer patients on chemotherapy, patients on immunomodulatory treatments for rheumatologic, gastrointestinal or other conditions, as well as those with other immunocompromis...

journal_title：Expert review of vaccines

authors： Kotton CN

更新日期：2008-07-01 00:00:00

abstract：:A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant pla...

journal_title：Expert review of vaccines

authors： Pushko P,Lukashevich IS,Weaver SC,Tretyakova I

更新日期：2016-09-01 00:00:00

abstract：INTRODUCTION:Due to overcome the hardness of the vaccine design, computational vaccinology is emerging widely. Prediction of T cell and B cell epitopes, antigen processing analysis, antigenicity analysis, population coverage, conservancy analysis, allergenicity assessment, toxicity prediction, and protein-peptide docki...

journal_title：Expert review of vaccines

authors： Kardani K,Bolhassani A,Namvar A

更新日期：2020-08-01 00:00:00

abstract：:Pneumococcal disease is a major health problem worldwide. Large, rapid declines in overall invasive pneumococcal disease and mucosal disease in children, reductions in vaccine-type disease in unvaccinated children and adults (indirect effects) and significant drops in antibiotic-resistant infections were observed afte...

journal_title：Expert review of vaccines

authors： Dinleyici EC,Yargic ZA

更新日期：2008-11-01 00:00:00

abstract：INTRODUCTION:Although much progress has been made in the last decade(s) toward development of effective cancer vaccines, there are still important obstacles to therapeutic successes. New generations of cancer vaccines will benefit from a combination adjuvant approach that targets multiple branches of the immune respons...

journal_title：Expert review of vaccines

authors： Bowen WS,Svrivastava AK,Batra L,Barsoumian H,Shirwan H

更新日期：2018-03-01 00:00:00

abstract：:Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the immune response elicited by coadministered vaccines. Combining CpG ODN with anthrax vaccine adsorbed (AVA), the licensed human vaccine, can increase the speed, magnitude and avidity of the resultant anti-ant...

journal_title：Expert review of vaccines

authors： Klinman DM

更新日期：2006-06-01 00:00:00

abstract：:Optimal vaccine efficacy requires not only a protective antigen, but also a strong immune activator as an adjuvant. Most viral vaccines, such as influenza vaccines and nonviral genetic vaccines (e.g., DNA vaccines), contain nucleic acids, which appear to act as essential 'built-in' adjuvants. Specific receptors, inclu...

journal_title：Expert review of vaccines

authors： Koyama S,Coban C,Aoshi T,Horii T,Akira S,Ishii KJ

更新日期：2009-08-01 00:00:00

abstract：:In the Second Conference on Controversies in Vaccination in Adults, leading vaccine experts among manufacturers, physicians, microbiologists, virologists, immunologists and public health specialists came together to discuss recent approaches, developments and strategies in vaccination against worldwide pressing epidem...

journal_title：Expert review of vaccines

authors： Doerr HW

更新日期：2013-06-01 00:00:00

abstract：:The management of advanced prostate cancer, specifically metastatic castrate-resistant prostate cancer (mCRPC), remains a therapeutic challenge. Sipuleucel-T (Provenge; APC8015) was approved by the FDA in 2010 for the treatment of asymptomatic or minimally symptomatic mCRPC patients, and it remains the only FDA-approv...

journal_title：Expert review of vaccines

authors： Wei XX,Fong L,Small EJ

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Patent and proprietary medicine vendors (PPMVs) are widespread in communities and can potentially be used to expand access to routine immunization especially in underserved areas. In this study, we aimed to assess their readiness to implement routine immunization in Kano, Nigeria and identify factors associa...

journal_title：Expert review of vaccines

authors： Adamu AA,Gadanya MA,Jalo RI,Uthman OA,Nnaji CA,Bello IW,Wiysonge CS

更新日期：2020-04-01 00:00:00

abstract：:Vaccine manufacturing processes are designed to meet present and upcoming challenges associated with a growing vaccine market and to include multi-use facilities offering a broad portfolio and faster reaction times in case of pandemics and emerging diseases. The final products, from whole viruses to recombinant viral ...

journal_title：Expert review of vaccines

authors： Gallo-Ramírez LE,Nikolay A,Genzel Y,Reichl U

更新日期：2015-01-01 00:00:00

abstract：:Although mass vaccination of the entire population of an endemic area would be the most cost-effective tool to diminish Leishmania burden, an effective vaccine is not yet commercially available. Practically, vaccines have failed to achieve the required level of protection, possibly owing to the lack of an appropriate ...

journal_title：Expert review of vaccines

authors： Doroud D,Rafati S

更新日期：2012-01-01 00:00:00

abstract：:Influenza inflicts significant global mortality and morbidity that can be combated by effective immunization. However, the protective efficacy of current vaccines is limited by both the significant antigenic diversity of the viral hemagglutinin protein and the capacity for rapid antigenic change. This necessitates glo...

journal_title：Expert review of vaccines

authors： Wheatley AK,Kent SJ

更新日期：2015-01-01 00:00:00